

YEAQ-0697-1303s

SANITIZED

PUBLIC COPY

June 25, 1997

Via Federal Express

8EHQ-91-1303

Document Processing Center (7407)
Attention: 8 (e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street SW
Washington, DC 20460-0001

8EHQ-91-1303

69970000 203s

RECEIVED
DPPT NCIC
97 JUN 25 11:17

Dear 8(e) Coordinator:

8EHQ-91-1303
Cymoxanil

This letter is to inform you of the results of a recently conducted acute oral toxicity study (LD50) in rats with a R&D proprietary mixture containing the above referenced test substance.

Groups of 5 male and 5 female Crl:CD[®]BR rats were fasted overnight and then administered the test mixture by intragastric intubation. After dosing, the rats were observed for mortality and clinical signs of toxicity over a 14-day observation period.

The proprietary R&D mixture contained Cymoxanil. Male and female rats were dosed at 241, 347, or 500 mg/kg. Mortality occurred in 0, 1, and 8 rats dosed at 241, 347, and 500 mg/kg, respectively. The LD50 was calculated to be 433 mg/kg.

Tremors were observed in surviving male and female rats dosed at 241 or 347 mg/kg and in a surviving female rat dosed at 500 mg/kg. Male and female rats in the 500 mg/kg dose group exhibited tremors before they were found dead up to 9 days after dosing. Hypoactivity was observed in surviving male and female rats in all dose groups. Male and female rats in the 500 mg/kg dose group exhibited tremors before they were found dead up to 9 days after dosing. Impaired righting reflex was observed in a surviving male rat dosed at 241 mg/kg and in male and female rats in the 500 mg/kg dose group before they were found dead up to 9 days after dosing. Ataxia was observed in surviving male rats in the 241 mg/kg dose group and in surviving female rats in all dose groups. Male and female rats in the 500 mg/kg dose group exhibited ataxia before they were found dead up to 9 days after dosing. A male rat dosed at 500 mg/kg exhibited convulsions 3 days after dosing and was found dead 8 days after dosing.

RECEIVED
DPPT NCIC
97 JUN 30 AM 8:39

SANITIZED

Under these experimental conditions, the clinical signs described above appear to be reportable, based upon EPA guidance regarding the reportability of such data under TSCA Section 8(e) criteria.

Sincerely,

Best Available Copy